Phase II Rectal + Chemotherapy

Authors: Hildebrandt B, Wust P, Dräger J, Lüdemann L, Sreenivasa G, Tullius SG, Amthauer H, Neuhaus P, Felix R, Riess H.
Publication: Int J Hyperthermia. 2004 Jun;20(4):359-69.

PURPOSE:
The aim of this study was to evaluate the feasibility and toxicity of a novel hyperthermic chemotherapy approach for patients with locally recurrent adenocarcinoma of the rectum. All patients were pre-irradiated (> or = 45 Gy) and had histologically proven pelvic recurrence.

Phase II Soft Tissue Sarcoma + Radiotherapy + Chemotherapy

Authors: Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, Hiddemann W, Issels RD.
Publication:J Clin Oncol. 2002 Jul 15;20(14):3156-64.

PURPOSE:
From 1991 to 1997, 58 patients with HR-STS at RP/V sites were prospectively treated with four cycles of etoposide, ifosfamide, and doxorubicin combined with RHT followed by surgery, adjuvant chemotherapy, and radiation.

Phase I/II Prostate + Radiotherapy

Authors: Kaplan I, Kapp DS, Bagshaw MA.
Publication: Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):551-4.

ABSTRACT:
At Stanford, six patients underwent a course of external radiotherapy after local recurrence following 125-iodine implantation.

Phase II Deep Tumor + Radiotherapy + Chemotherapy

Authors: Tilly W, Wust P, Rau B, Harder C, Gellermann J, Schlag P, Budach V, Felix R.
Publication: Int J Hyperthermia. 2001 Mar-Apr;17(2):172-88.

PURPOSE:
The system BSD 2000 has been in clinical use for regional hyperthermia for more than 10 years. Several technical details of this hyperthermia system, as well as the results of clinical studies employing this system have been investigated. The intention of this paper is to investigate the correlation between technical efficiency or feasibility of hyperthermia with the BSD 2000, in terms of power densities and temperatures depending upon parameters such as tumour histology, tumour location, patient age, patient sex, and patient cross section.

Phase III Cervical + Radiotherapy

Authors: van der Zee J, González GD.
Publication: Int J Hyperthermia. 2002 Jan-Feb;18(1):1-12.

BACKGROUND:
Radiotherapy plus hyperthermia was compared to radiotherapy alone in the Dutch Deep Hyperthermia Trial, in patients with advanced bladder, cervical, and rectal tumours. The overall results, published elsewhere, demonstrate that addition of hyperthermia to radiotherapy improves both pelvic control and overall survival rates. The therapeutic gain appeared especially worthwhile in locally advanced cervical tumours. Here, the results in patients with cervical cancer are summarized and discussed, and further details provided.

Phase I/II Soft Tissue Sarcoma + Radiotherapy

Authors: Prosnitz LR, Maguire P, Anderson JM, Scully SP, Harrelson JM, Jones EL, Dewhirst M, Samulski TV, Powers BE, Rosner GL, Dodge RK, Layfield L, Clough R, Brizel DM.
Publication: Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):941-9.

PURPOSE:
To explore the use of a novel program of preoperative radiation and hyperthermia in the management of high-grade soft tissue sarcomas (STS).

Phase II Soft Tissue Sarcoma + Radiotherapy + Chemotherapy

Authors: Schlemmer M, Wendtner CM, Lindner L, Abdel-Rahman S, Hiddemann W, Issels RD.
Publication: Int J Hyperthermia. 2010;26(2):127-35. doi: 10.3109/02656730903335995.

PURPOSE:

We report data from phase II trials examining the efficacy of multimodality treatment with neoadjuvant chemotherapy, hyperthermia, surgery, radiation and postoperative thermochemotherapy in adult patients with high-risk sarcomas of the extremities.

Phase I Germ cell + Chemotherapy

Authors: Schneider DT, Wessalowski R, Calaminus G, Pape H, Bamberg M, Engert J, Waag K, Gadner H, Göbel U.
Publication: J Clin Oncol. 2001 Apr 1;19(7):1951-60.

PURPOSE:

To evaluate therapeutic options for recurrent malignant sacrococcygeal germ cell tumors (GCT) following three-agent, cisplatinum-based, first-line chemotherapy and tumor resection.

Pilot Study Pediatric Germ Cell + Radiotherapy + Chemotherapy

Authors: Wessalowski R, Blohm M, Calaminus G, Engert J, Harms D, Krause I, Kruck H, Grüttner HP, Pape H, Göbel U.
Publication: Klin Padiatr. 1997 Jul-Aug;209(4):250-6.

PURPOSE:
In this study treatment results in children and adolescents (n = 32) suffering from loco-regional abdominal relapses of germ cell tumors (GCT) (7 embryonal carcinoma, 17 Yolk sac tumors, 8 immature teratomas) aged from 1;0 to 23;3 years (mean = 10;11 years) were evaluated.